Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jun 15;83(2):232–238. doi: 10.1054/bjoc.1999.1232

Biodistribution and pharmacokinetics of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies

K J Harrington 1,2, G Rowlinson-Busza 1, K N Syrigos 1, P S Uster 3, R M Abra 3, J S W Stewart 4
PMCID: PMC2363473  PMID: 10901376

Abstract

The biodistribution and pharmacokinetics of111In-DTPA-labelled pegylated liposomes in tumour-bearing nude mice was studied to examine possible applications of pegylated liposome-targeted anti-cancer therapies. Nude mice received an intravenous injection of 100 μl of111In-DTPA-labelled pegylated liposomes, containing 0.37–0.74 MBq of activity. The t 1/2α and t 1/2β of111In-DTPA-labelled pegylated liposomes were 1.1 and 10.3 h, respectively. Tumour uptake was maximal at 24 h at 5.5 ± 3.0% ID g–1. Significant reticuloendothelial system uptake was demonstrated with 19.3 ± 2.8 and 18.8 ± 4.2% ID g–1at 24 h in the liver and spleen, respectively. Other sites of appreciable deposition were the kidney, skin, female reproductive tract and to a lesser extent the gastrointestinal tract. There was no indication of cumulative deposition of pegylated liposomes in the lung, central nervous system, musculoskeletal system, heart or adrenal glands. In contrast, the t 1/2α and t 1/2β of unencapsulated111In-DTPA were 5 min and 1.1 h, respectively, with no evidence of accumulation in tumour or normal tissues. Incubation of111In-DTPA-labelled pegylated liposomes in human serum for up to 10 days confirmed that they are very stable, with only minor leakage of their contents. The potential applications of pegylated liposomes in the arena of targeted therapy of solid cancers are discussed. © 2000 Cancer Research Campaign

Keywords: biodistribution, head and neck cancer, pegylated liposomes, pharmacokinetics, tumour targeting, xenograft tumour

Full Text

The Full Text of this article is available as a PDF (83.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen T. M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 1987 Oct 19;223(1):42–46. doi: 10.1016/0014-5793(87)80506-9. [DOI] [PubMed] [Google Scholar]
  2. Bangham A. D., Standish M. M., Watkins J. C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965 Aug;13(1):238–252. doi: 10.1016/s0022-2836(65)80093-6. [DOI] [PubMed] [Google Scholar]
  3. Britten R. A., Evans A. J., Allalunis-Turner M. J., Pearcey R. G. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):367–374. doi: 10.1016/0360-3016(95)02088-8. [DOI] [PubMed] [Google Scholar]
  4. EAGLE H. Propagation in a fluid medium of a human epidermoid carcinoma, strain KB. Proc Soc Exp Biol Med. 1955 Jul;89(3):362–364. doi: 10.3181/00379727-89-21811. [DOI] [PubMed] [Google Scholar]
  5. Gabizon A. A. Liposomal anthracyclines. Hematol Oncol Clin North Am. 1994 Apr;8(2):431–450. [PubMed] [Google Scholar]
  6. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994 Feb 15;54(4):987–992. [PubMed] [Google Scholar]
  7. Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6949–6953. doi: 10.1073/pnas.85.18.6949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goebel F. D., Goldstein D., Goos M., Jablonowski H., Stewart J. S. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br J Cancer. 1996 Apr;73(8):989–994. doi: 10.1038/bjc.1996.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gordon K. B., Tajuddin A., Guitart J., Kuzel T. M., Eramo L. R., VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer. 1995 Apr 15;75(8):2169–2173. doi: 10.1002/1097-0142(19950415)75:8<2169::aid-cncr2820750822>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  10. Gregoriadis G., Wills E. J., Swain C. P., Tavill A. S. Drug-carrier potential of liposomes in cancer chemotherapy. Lancet. 1974 Jun 29;1(7870):1313–1316. doi: 10.1016/s0140-6736(74)90682-5. [DOI] [PubMed] [Google Scholar]
  11. Harrison M., Tomlinson D., Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1995 Apr;13(4):914–920. doi: 10.1200/JCO.1995.13.4.914. [DOI] [PubMed] [Google Scholar]
  12. Huang S. K., Lee K. D., Hong K., Friend D. S., Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 1992 Oct 1;52(19):5135–5143. [PubMed] [Google Scholar]
  13. Huang S. K., Martin F. J., Jay G., Vogel J., Papahadjopoulos D., Friend D. S. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol. 1993 Jul;143(1):10–14. [PMC free article] [PubMed] [Google Scholar]
  14. Lasic D. D., Papahadjopoulos D. Liposomes revisited. Science. 1995 Mar 3;267(5202):1275–1276. doi: 10.1126/science.7871422. [DOI] [PubMed] [Google Scholar]
  15. Madhavan S., Northfelt D. W. Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst. 1995 Oct 18;87(20):1556–1557. doi: 10.1093/jnci/87.20.1556. [DOI] [PubMed] [Google Scholar]
  16. Maraveyas A., Stafford N., Rowlinson-Busza G., Stewart J. S., Epenetos A. A. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Cancer Res. 1995 Mar 1;55(5):1060–1069. [PubMed] [Google Scholar]
  17. Mayhew E. G., Lasic D., Babbar S., Martin F. J. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int J Cancer. 1992 May 8;51(2):302–309. doi: 10.1002/ijc.2910510221. [DOI] [PubMed] [Google Scholar]
  18. McGinn C. J., Kinsella T. J. The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol. 1992 Aug;19(4 Suppl 11):21–28. [PubMed] [Google Scholar]
  19. Muggia F. M., Hainsworth J. D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997 Mar;15(3):987–993. doi: 10.1200/JCO.1997.15.3.987. [DOI] [PubMed] [Google Scholar]
  20. Newman M. S., Colbern G. T., Working P. K., Engbers C., Amantea M. A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43(1):1–7. doi: 10.1007/s002800050855. [DOI] [PubMed] [Google Scholar]
  21. Ng T. T., Denning D. W. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med. 1995 May 22;155(10):1093–1098. [PubMed] [Google Scholar]
  22. Northfelt D. W., Dezube B. J., Thommes J. A., Miller B. J., Fischl M. A., Friedman-Kien A., Kaplan L. D., Du Mond C., Mamelok R. D., Henry D. H. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445–2451. doi: 10.1200/JCO.1998.16.7.2445. [DOI] [PubMed] [Google Scholar]
  23. Papahadjopoulos D., Allen T. M., Gabizon A., Mayhew E., Matthay K., Huang S. K., Lee K. D., Woodle M. C., Lasic D. D., Redemann C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460–11464. doi: 10.1073/pnas.88.24.11460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ranson M. R., Carmichael J., O'Byrne K., Stewart S., Smith D., Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol. 1997 Oct;15(10):3185–3191. doi: 10.1200/JCO.1997.15.10.3185. [DOI] [PubMed] [Google Scholar]
  25. Russo R., Nigro L. C., Minniti S., Montineri A., Gradoni L., Caldeira L., Davidson R. N. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect. 1996 Mar;32(2):133–137. doi: 10.1016/s0163-4453(96)91343-2. [DOI] [PubMed] [Google Scholar]
  26. Saunders M., Dische S. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer Suppl. 1996 Jul;27:S271–S278. [PMC free article] [PubMed] [Google Scholar]
  27. Siegal T., Horowitz A., Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg. 1995 Dec;83(6):1029–1037. doi: 10.3171/jns.1995.83.6.1029. [DOI] [PubMed] [Google Scholar]
  28. Stewart S., Jablonowski H., Goebel F. D., Arasteh K., Spittle M., Rios A., Aboulafia D., Galleshaw J., Dezube B. J. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998 Feb;16(2):683–691. doi: 10.1200/JCO.1998.16.2.683. [DOI] [PubMed] [Google Scholar]
  29. Urba S. Combined-modality treatment of esophageal cancer. Oncology (Williston Park) 1997 Sep;11(9 Suppl 9):63–67. [PubMed] [Google Scholar]
  30. Vaage J., Barberá-Guillem E., Abra R., Huang A., Working P. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer. 1994 Mar 1;73(5):1478–1484. doi: 10.1002/1097-0142(19940301)73:5<1478::aid-cncr2820730526>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  31. Vaage J., Donovan D., Loftus T., Working P. Prevention of metastasis from mouse mammary carcinomas with liposomes carrying doxorubicin. Br J Cancer. 1995 Nov;72(5):1074–1075. doi: 10.1038/bjc.1995.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vaage J., Donovan D., Mayhew E., Abra R., Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer. 1993 Dec 15;72(12):3671–3675. doi: 10.1002/1097-0142(19931215)72:12<3671::aid-cncr2820721219>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  33. Vaage J., Donovan D., Mayhew E., Uster P., Woodle M. Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes. Int J Cancer. 1993 Jul 30;54(6):959–964. doi: 10.1002/ijc.2910540616. [DOI] [PubMed] [Google Scholar]
  34. Vaage J., Donovan D., Wipff E., Abra R., Colbern G., Uster P., Working P. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer. 1999 Jan 5;80(1):134–137. doi: 10.1002/(sici)1097-0215(19990105)80:1<134::aid-ijc24>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  35. Vaage J., Mayhew E., Lasic D., Martin F. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer. 1992 Jul 30;51(6):942–948. doi: 10.1002/ijc.2910510618. [DOI] [PubMed] [Google Scholar]
  36. Williams S. S., Alosco T. R., Mayhew E., Lasic D. D., Martin F. J., Bankert R. B. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res. 1993 Sep 1;53(17):3964–3967. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES